These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 6372686)

  • 1. Ceftazidime in the treatment of pediatric patients with severe urinary tract infections due to Pseudomonas spp.
    Rusconi F; Assael BM; Florioli A; Zaffaroni G
    Antimicrob Agents Chemother; 1984 Mar; 25(3):395-7. PubMed ID: 6372686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftazidime as a single agent in the treatment of severe Pseudomonas aeruginosa infections.
    Clumeck N; Gordts B; Dab I; Jaspar N; Van Laethem Y; Butzler JP
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():207-11. PubMed ID: 6352620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacology of ceftazidime in paediatrics.
    Assael BM; Boccazzi A; Caccamo ML; Giunta A; Marini A; Padoan R; Rusconi F; Sereni F
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():341-6. PubMed ID: 6352640
    [No Abstract]   [Full Text] [Related]  

  • 4. A random comparative trial of 0.25, 0.5 and 1.0 g ceftazidime twice daily in urinary tract infection.
    Gentry LO; Douthit MB; Childs SJ; Madsen PO
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():53-7. PubMed ID: 6352655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftazidime in the treatment of urinary tract infection.
    Kasanen A; Nikoskelainen J; Saarimaa H; Toivanen P
    Curr Med Res Opin; 1982; 8(4):266-73. PubMed ID: 6817972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of ceftazidime and tobramycin in the treatment of complicated urinary tract infections.
    Cox CE
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():47-52. PubMed ID: 6352654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the usefulness of a novel injectable cephalosporin, E1040, and ceftazidime for management of complicated urinary tract infections caused by Pseudomonas aeruginosa and Proteus mirabilis by using the rat urolithiasis model.
    Satoh M; Munakata K; Takeuchi H; Yoshida O
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1580-3. PubMed ID: 1510458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftazidime in patients with severe Pseudomonas infections.
    Lechi A; Arosio E; Montesi G; Vaona B; Ghidini O; Parrinello E
    Int J Clin Pharmacol Ther Toxicol; 1986 Mar; 24(3):159-64. PubMed ID: 3516892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftazidime therapy for serious infections.
    Bint AJ; Constable J; Patton KR; Constable FL
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():115-21. PubMed ID: 6352613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of ceftazidime. Treatment of serious infection due to multiresistant Pseudomonas and other gram-negative bacteria.
    Scully BE; Neu HC
    Arch Intern Med; 1984 Jan; 144(1):57-62. PubMed ID: 6419690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms.
    Clumeck N; Van Laethem Y; Gordts B; Jaspar N; Butzler JP
    Antimicrob Agents Chemother; 1983 Aug; 24(2):176-80. PubMed ID: 6357068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with ceftazidime in urology in Japan.
    Kawamura N
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():65-70. PubMed ID: 6352657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftazidime in the treatment of chronic suppurative otitis media in children.
    Lautala P; Vare M; Vuorinen O; Kaar ML
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():365-7. PubMed ID: 6352646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftazidime: a new approach in the treatment of moderate and severe infections.
    Abbas AM; Taylor MC; Newby D; Jones RB; Rigby CC; Haste AR; Cantor AM
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():147-52. PubMed ID: 6352615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
    Gentile I; Maraolo AE; Borgia G
    Expert Rev Anti Infect Ther; 2016 Oct; 14(10):875-8. PubMed ID: 27599088
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects.
    Gentry LO; Rodriguez-Gomez G
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2371-4. PubMed ID: 1804010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aztreonam in the treatment of severe urinary tract infections in pediatric patients.
    Rusconi F; Assael BM; Boccazzi A; Colombo R; Crossignani RM; Garlaschi L; Rancilio L
    Antimicrob Agents Chemother; 1986 Aug; 30(2):310-4. PubMed ID: 3094442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open study of the use of ceftazidime in Gram-negative infections.
    Wardle JK; Snow MH; Ingham HR; Selkon JB
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():389-93. PubMed ID: 6352650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effectiveness of recent cephalosporins against urinary tract and wound infection bacteria including Pseudomonas aeruginosa].
    Ortel S
    Z Gesamte Hyg; 1982 Aug; 28(8):545-51. PubMed ID: 7136065
    [No Abstract]   [Full Text] [Related]  

  • 20. Cefsulodin and ceftazidime, two antipseudomonal cephalosporins.
    Smith BR
    Clin Pharm; 1984; 3(4):373-85. PubMed ID: 6380902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.